Timeline
CelLBxHealth
CelLBxHealth study backs Parsortix for ADC target detection
CelLBxHealth halves cash burn as Q2 revenue doubles
CelLBxHealth reaffirms FY2026 revenue target of £2.1 million
CelLBxHealth revenues halve as turnaround cuts costs and sets 2026 growth target
CelLBxHealth shares rocket on AstraZeneca master services agreement
CelLBxHealth to deploy Parsortix with AdventHealth for two US clinical studies
CelLBxHealth sets FY 2026 revenue floor at £2.1m
CelLBxHealth partners with The Royal Marsden on 200‑patient CTC study
More in Biotech
GENinCode genetic test cuts cardiac risk in Catalonia pilot
A real-world pilot by Catalonia's health service found GENinCode's CARDIO inCode-Score reclassified risk in over 40% of moderate-risk patients and drove measurable improvements in cholesterol and smoking cessation.